You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's al…
Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...
Cure Today2h
Clinical Trials to Watch in Triple-Negative Breast Cancer
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.
pharmaphorum4h
Can Keytruda finally break into early head and neck cancer?
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
Pharmaceutical Technology50m
Eikon raises almost $351m to advance cancer candidates through the clinic
Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.
Merck's Oncology Strength: Beating Wall Street Again
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
Pharm Exec1d
FDA Grants Priority Review to Merck’s Keytruda for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
Merck’s application for keytruda in HNSCC granted priority review by FDA
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
BioPharma Dive6h
Eikon raises $351M in one of the year’s largest biotech venture rounds
The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...
PharmaTimes8h
Microbiotica unveils new data on MB097 at AACR IO meeting
Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.
Medicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11
Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...